Global Targeted Protein Degrader Technology Market 2024 by Company, Regions, Type and Application, Forecast to 2030
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Targeted Protein Degrader Technology by Type
- 1.3.1 Overview: Global Targeted Protein Degrader Technology Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Targeted Protein Degrader Technology Consumption Value Market Share by Type in 2023
- 1.3.3 Molecular Glues (CELMoDTM Agents)
- 1.3.4 Ligand-directed Degraders (LDDs)
- 1.3.5 Antibody Drug Conjugate (ADC) Degraders
- 1.4 Global Targeted Protein Degrader Technology Market by Application
- 1.4.1 Overview: Global Targeted Protein Degrader Technology Market Size by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Prostate Cancer
- 1.4.3 Breast Cancer
- 1.4.4 Lymphoma
- 1.4.5 Others
- 1.5 Global Targeted Protein Degrader Technology Market Size & Forecast
- 1.6 Global Targeted Protein Degrader Technology Market Size and Forecast by Region
- 1.6.1 Global Targeted Protein Degrader Technology Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Targeted Protein Degrader Technology Market Size by Region, (2019-2030)
- 1.6.3 North America Targeted Protein Degrader Technology Market Size and Prospect (2019-2030)
- 1.6.4 Europe Targeted Protein Degrader Technology Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Targeted Protein Degrader Technology Market Size and Prospect (2019-2030)
- 1.6.6 South America Targeted Protein Degrader Technology Market Size and Prospect (2019-2030)
- 1.6.7 Middle East & Africa Targeted Protein Degrader Technology Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 Arvinas
- 2.1.1 Arvinas Details
- 2.1.2 Arvinas Major Business
- 2.1.3 Arvinas Targeted Protein Degrader Technology Product and Solutions
- 2.1.4 Arvinas Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Arvinas Recent Developments and Future Plans
- 2.2 Kymera Therapeutics
- 2.2.1 Kymera Therapeutics Details
- 2.2.2 Kymera Therapeutics Major Business
- 2.2.3 Kymera Therapeutics Targeted Protein Degrader Technology Product and Solutions
- 2.2.4 Kymera Therapeutics Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Kymera Therapeutics Recent Developments and Future Plans
- 2.3 Dialectic Therapeutics
- 2.3.1 Dialectic Therapeutics Details
- 2.3.2 Dialectic Therapeutics Major Business
- 2.3.3 Dialectic Therapeutics Targeted Protein Degrader Technology Product and Solutions
- 2.3.4 Dialectic Therapeutics Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Dialectic Therapeutics Recent Developments and Future Plans
- 2.4 Bristol-Myers Squibb
- 2.4.1 Bristol-Myers Squibb Details
- 2.4.2 Bristol-Myers Squibb Major Business
- 2.4.3 Bristol-Myers Squibb Targeted Protein Degrader Technology Product and Solutions
- 2.4.4 Bristol-Myers Squibb Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
- 2.5 Nurix
- 2.5.1 Nurix Details
- 2.5.2 Nurix Major Business
- 2.5.3 Nurix Targeted Protein Degrader Technology Product and Solutions
- 2.5.4 Nurix Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Nurix Recent Developments and Future Plans
- 2.6 Cullgen
- 2.6.1 Cullgen Details
- 2.6.2 Cullgen Major Business
- 2.6.3 Cullgen Targeted Protein Degrader Technology Product and Solutions
- 2.6.4 Cullgen Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.6.5 Cullgen Recent Developments and Future Plans
- 2.7 C4 Therapeutics
- 2.7.1 C4 Therapeutics Details
- 2.7.2 C4 Therapeutics Major Business
- 2.7.3 C4 Therapeutics Targeted Protein Degrader Technology Product and Solutions
- 2.7.4 C4 Therapeutics Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 C4 Therapeutics Recent Developments and Future Plans
- 2.8 Foghorn
- 2.8.1 Foghorn Details
- 2.8.2 Foghorn Major Business
- 2.8.3 Foghorn Targeted Protein Degrader Technology Product and Solutions
- 2.8.4 Foghorn Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.8.5 Foghorn Recent Developments and Future Plans
- 2.9 Novartis
- 2.9.1 Novartis Details
- 2.9.2 Novartis Major Business
- 2.9.3 Novartis Targeted Protein Degrader Technology Product and Solutions
- 2.9.4 Novartis Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.9.5 Novartis Recent Developments and Future Plans
- 2.10 Pfizer
- 2.10.1 Pfizer Details
- 2.10.2 Pfizer Major Business
- 2.10.3 Pfizer Targeted Protein Degrader Technology Product and Solutions
- 2.10.4 Pfizer Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.10.5 Pfizer Recent Developments and Future Plans
- 2.11 MSD
- 2.11.1 MSD Details
- 2.11.2 MSD Major Business
- 2.11.3 MSD Targeted Protein Degrader Technology Product and Solutions
- 2.11.4 MSD Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.11.5 MSD Recent Developments and Future Plans
- 2.12 Origami Therapeutics
- 2.12.1 Origami Therapeutics Details
- 2.12.2 Origami Therapeutics Major Business
- 2.12.3 Origami Therapeutics Targeted Protein Degrader Technology Product and Solutions
- 2.12.4 Origami Therapeutics Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.12.5 Origami Therapeutics Recent Developments and Future Plans
- 2.13 NEOsphere Biotechnologies
- 2.13.1 NEOsphere Biotechnologies Details
- 2.13.2 NEOsphere Biotechnologies Major Business
- 2.13.3 NEOsphere Biotechnologies Targeted Protein Degrader Technology Product and Solutions
- 2.13.4 NEOsphere Biotechnologies Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.13.5 NEOsphere Biotechnologies Recent Developments and Future Plans
- 2.14 Dunad Therapeutics
- 2.14.1 Dunad Therapeutics Details
- 2.14.2 Dunad Therapeutics Major Business
- 2.14.3 Dunad Therapeutics Targeted Protein Degrader Technology Product and Solutions
- 2.14.4 Dunad Therapeutics Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.14.5 Dunad Therapeutics Recent Developments and Future Plans
- 2.15 Entact Bio
- 2.15.1 Entact Bio Details
- 2.15.2 Entact Bio Major Business
- 2.15.3 Entact Bio Targeted Protein Degrader Technology Product and Solutions
- 2.15.4 Entact Bio Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.15.5 Entact Bio Recent Developments and Future Plans
- 2.16 Proxygen
- 2.16.1 Proxygen Details
- 2.16.2 Proxygen Major Business
- 2.16.3 Proxygen Targeted Protein Degrader Technology Product and Solutions
- 2.16.4 Proxygen Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.16.5 Proxygen Recent Developments and Future Plans
- 2.17 Monte Rosa Therapeutics
- 2.17.1 Monte Rosa Therapeutics Details
- 2.17.2 Monte Rosa Therapeutics Major Business
- 2.17.3 Monte Rosa Therapeutics Targeted Protein Degrader Technology Product and Solutions
- 2.17.4 Monte Rosa Therapeutics Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.17.5 Monte Rosa Therapeutics Recent Developments and Future Plans
- 2.18 Treeline Biosciences
- 2.18.1 Treeline Biosciences Details
- 2.18.2 Treeline Biosciences Major Business
- 2.18.3 Treeline Biosciences Targeted Protein Degrader Technology Product and Solutions
- 2.18.4 Treeline Biosciences Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.18.5 Treeline Biosciences Recent Developments and Future Plans
- 2.19 Ubiquigent
- 2.19.1 Ubiquigent Details
- 2.19.2 Ubiquigent Major Business
- 2.19.3 Ubiquigent Targeted Protein Degrader Technology Product and Solutions
- 2.19.4 Ubiquigent Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.19.5 Ubiquigent Recent Developments and Future Plans
- 2.20 Kangpu Biopharmaceuticals
- 2.20.1 Kangpu Biopharmaceuticals Details
- 2.20.2 Kangpu Biopharmaceuticals Major Business
- 2.20.3 Kangpu Biopharmaceuticals Targeted Protein Degrader Technology Product and Solutions
- 2.20.4 Kangpu Biopharmaceuticals Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.20.5 Kangpu Biopharmaceuticals Recent Developments and Future Plans
- 2.21 Ranok Therapeutics
- 2.21.1 Ranok Therapeutics Details
- 2.21.2 Ranok Therapeutics Major Business
- 2.21.3 Ranok Therapeutics Targeted Protein Degrader Technology Product and Solutions
- 2.21.4 Ranok Therapeutics Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.21.5 Ranok Therapeutics Recent Developments and Future Plans
- 2.22 Accutar Biotech
- 2.22.1 Accutar Biotech Details
- 2.22.2 Accutar Biotech Major Business
- 2.22.3 Accutar Biotech Targeted Protein Degrader Technology Product and Solutions
- 2.22.4 Accutar Biotech Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.22.5 Accutar Biotech Recent Developments and Future Plans
- 2.23 BeiGene
- 2.23.1 BeiGene Details
- 2.23.2 BeiGene Major Business
- 2.23.3 BeiGene Targeted Protein Degrader Technology Product and Solutions
- 2.23.4 BeiGene Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.23.5 BeiGene Recent Developments and Future Plans
- 2.24 Hinova Pharma
- 2.24.1 Hinova Pharma Details
- 2.24.2 Hinova Pharma Major Business
- 2.24.3 Hinova Pharma Targeted Protein Degrader Technology Product and Solutions
- 2.24.4 Hinova Pharma Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.24.5 Hinova Pharma Recent Developments and Future Plans
- 2.25 Haisco Pharmaceutical
- 2.25.1 Haisco Pharmaceutical Details
- 2.25.2 Haisco Pharmaceutical Major Business
- 2.25.3 Haisco Pharmaceutical Targeted Protein Degrader Technology Product and Solutions
- 2.25.4 Haisco Pharmaceutical Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.25.5 Haisco Pharmaceutical Recent Developments and Future Plans
- 2.26 CTTQ
- 2.26.1 CTTQ Details
- 2.26.2 CTTQ Major Business
- 2.26.3 CTTQ Targeted Protein Degrader Technology Product and Solutions
- 2.26.4 CTTQ Targeted Protein Degrader Technology Revenue, Gross Margin and Market Share (2019-2024)
- 2.26.5 CTTQ Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Targeted Protein Degrader Technology Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Targeted Protein Degrader Technology by Company Revenue
- 3.2.2 Top 3 Targeted Protein Degrader Technology Players Market Share in 2023
- 3.2.3 Top 6 Targeted Protein Degrader Technology Players Market Share in 2023
- 3.3 Targeted Protein Degrader Technology Market: Overall Company Footprint Analysis
- 3.3.1 Targeted Protein Degrader Technology Market: Region Footprint
- 3.3.2 Targeted Protein Degrader Technology Market: Company Product Type Footprint
- 3.3.3 Targeted Protein Degrader Technology Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Targeted Protein Degrader Technology Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Targeted Protein Degrader Technology Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
- 5.1 Global Targeted Protein Degrader Technology Consumption Value Market Share by Application (2019-2024)
- 5.2 Global Targeted Protein Degrader Technology Market Forecast by Application (2025-2030)
6 North America
- 6.1 North America Targeted Protein Degrader Technology Consumption Value by Type (2019-2030)
- 6.2 North America Targeted Protein Degrader Technology Market Size by Application (2019-2030)
- 6.3 North America Targeted Protein Degrader Technology Market Size by Country
- 6.3.1 North America Targeted Protein Degrader Technology Consumption Value by Country (2019-2030)
- 6.3.2 United States Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 6.3.3 Canada Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe Targeted Protein Degrader Technology Consumption Value by Type (2019-2030)
- 7.2 Europe Targeted Protein Degrader Technology Consumption Value by Application (2019-2030)
- 7.3 Europe Targeted Protein Degrader Technology Market Size by Country
- 7.3.1 Europe Targeted Protein Degrader Technology Consumption Value by Country (2019-2030)
- 7.3.2 Germany Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 7.3.3 France Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 7.3.5 Russia Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 7.3.6 Italy Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific Targeted Protein Degrader Technology Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Targeted Protein Degrader Technology Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific Targeted Protein Degrader Technology Market Size by Region
- 8.3.1 Asia-Pacific Targeted Protein Degrader Technology Consumption Value by Region (2019-2030)
- 8.3.2 China Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 8.3.3 Japan Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 8.3.5 India Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 8.3.7 Australia Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America Targeted Protein Degrader Technology Consumption Value by Type (2019-2030)
- 9.2 South America Targeted Protein Degrader Technology Consumption Value by Application (2019-2030)
- 9.3 South America Targeted Protein Degrader Technology Market Size by Country
- 9.3.1 South America Targeted Protein Degrader Technology Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa Targeted Protein Degrader Technology Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Targeted Protein Degrader Technology Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa Targeted Protein Degrader Technology Market Size by Country
- 10.3.1 Middle East & Africa Targeted Protein Degrader Technology Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
- 10.3.4 UAE Targeted Protein Degrader Technology Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 Targeted Protein Degrader Technology Market Drivers
- 11.2 Targeted Protein Degrader Technology Market Restraints
- 11.3 Targeted Protein Degrader Technology Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Targeted Protein Degrader Technology Industry Chain
- 12.2 Targeted Protein Degrader Technology Upstream Analysis
- 12.3 Targeted Protein Degrader Technology Midstream Analysis
- 12.4 Targeted Protein Degrader Technology Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
Targeted protein degradation technology involves the design and development of small molecules or biologics that selectively bind to specific proteins within cells and mark them for degradation by the cell's natural protein degradation machinery, such as the ubiquitin-proteasome system or lysosomes. This approach enables the removal of disease-causing or undesirable proteins, including those considered "undruggable" by traditional small molecule inhibitors, by harnessing the body's own degradation pathways. Typically, targeted protein degraders consist of a ligand that binds to the target protein, a linker, and a component that recruits the cellular degradation machinery. This technology holds promise for the treatment of various diseases, including cancer and genetic disorders, by targeting proteins involved in disease pathways with high specificity and efficacy.
According to our (Global Info Research) latest study, the global Targeted Protein Degrader Technology market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Targeted Protein Degrader Technology market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Targeted Protein Degrader Technology market size and forecasts, in consumption value ($ Million), 2019-2030
Global Targeted Protein Degrader Technology market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Targeted Protein Degrader Technology market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Targeted Protein Degrader Technology market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Targeted Protein Degrader Technology
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Targeted Protein Degrader Technology market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Arvinas, Kymera Therapeutics, Dialectic Therapeutics, Bristol-Myers Squibb, Nurix, Cullgen, C4 Therapeutics, Foghorn, Novartis, Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Targeted Protein Degrader Technology market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Targeted Protein Degrader Technology market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Molecular Glues (CELMoDTM Agents)
Ligand-directed Degraders (LDDs)
Antibody Drug Conjugate (ADC) Degraders
Market segment by Application
Prostate Cancer
Breast Cancer
Lymphoma
Others
Market segment by players, this report covers
Arvinas
Kymera Therapeutics
Dialectic Therapeutics
Bristol-Myers Squibb
Nurix
Cullgen
C4 Therapeutics
Foghorn
Novartis
Pfizer
MSD
Origami Therapeutics
NEOsphere Biotechnologies
Dunad Therapeutics
Entact Bio
Proxygen
Monte Rosa Therapeutics
Treeline Biosciences
Ubiquigent
Kangpu Biopharmaceuticals
Ranok Therapeutics
Accutar Biotech
BeiGene
Hinova Pharma
Haisco Pharmaceutical
CTTQ
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Targeted Protein Degrader Technology product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Targeted Protein Degrader Technology, with revenue, gross margin, and global market share of Targeted Protein Degrader Technology from 2019 to 2024.
Chapter 3, the Targeted Protein Degrader Technology competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Targeted Protein Degrader Technology market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Targeted Protein Degrader Technology.
Chapter 13, to describe Targeted Protein Degrader Technology research findings and conclusion.